180 related articles for article (PubMed ID: 36465606)
1. Decreased expression of Glucagon-like peptide-1 receptor and Sodium-glucose co-transporter 2 in patients with proliferative diabetic retinopathy.
Chen H; Zhang X; Liao N; Ji Y; Mi L; Gan Y; Su Y; Wen F
Front Endocrinol (Lausanne); 2022; 13():1020252. PubMed ID: 36465606
[TBL] [Abstract][Full Text] [Related]
2. Correlations between vitreous cytokine levels and inflammatory cells in fibrovascular membranes of patients with proliferative diabetic retinopathy.
Urbančič M; Petrovič D; Živin AM; Korošec P; Fležar M; Petrovič MG
Mol Vis; 2020; 26():472-482. PubMed ID: 32606566
[TBL] [Abstract][Full Text] [Related]
3. Glucagon-like peptide-1 receptor (GLP-1R) signaling ameliorates dysfunctional immunity in COPD patients.
Huang J; Yi H; Zhao C; Zhang Y; Zhu L; Liu B; He P; Zhou M
Int J Chron Obstruct Pulmon Dis; 2018; 13():3191-3202. PubMed ID: 30349227
[TBL] [Abstract][Full Text] [Related]
4. Sodium-glucose co-transporter (SGLT)2 and SGLT1 renal expression in patients with type 2 diabetes.
Solini A; Rossi C; Mazzanti CM; Proietti A; Koepsell H; Ferrannini E
Diabetes Obes Metab; 2017 Sep; 19(9):1289-1294. PubMed ID: 28419670
[TBL] [Abstract][Full Text] [Related]
5. SGLT2 inhibitors and diabetic retinopathy progression.
Nadelmann JB; Miller CG; McGeehan B; Yu Y; VanderBeek BL
Graefes Arch Clin Exp Ophthalmol; 2024 Mar; 262(3):753-758. PubMed ID: 37847267
[TBL] [Abstract][Full Text] [Related]
6. Identification of proteins associated with clinical and pathological features of proliferative diabetic retinopathy in vitreous and fibrovascular membranes.
Klaassen I; de Vries EW; Vogels IMC; van Kampen AHC; Bosscha MI; Steel DHW; Van Noorden CJF; Lesnik-Oberstein SY; Schlingemann RO
PLoS One; 2017; 12(11):e0187304. PubMed ID: 29095861
[TBL] [Abstract][Full Text] [Related]
7. Inflammation and diabetic retinopathy.
Ucgun NI; Zeki-Fikret C; Yildirim Z
Mol Vis; 2020; 26():718-721. PubMed ID: 33209014
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-like peptide-1 receptor expression in the human eye.
Hebsgaard JB; Pyke C; Yildirim E; Knudsen LB; Heegaard S; Kvist PH
Diabetes Obes Metab; 2018 Sep; 20(9):2304-2308. PubMed ID: 29707863
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of SIRT6 and NMNAT2 is associated with proliferative diabetic retinopathy.
Chen H; Zhang X; Liao N; Ji Y; Mi L; Gan Y; Su Y; Wen F
Mol Vis; 2023; 29():160-168. PubMed ID: 38222451
[TBL] [Abstract][Full Text] [Related]
10. Th17 cell frequency and IL-17A concentrations in peripheral blood mononuclear cells and vitreous fluid from patients with diabetic retinopathy.
Chen H; Ren X; Liao N; Wen F
J Int Med Res; 2016 Dec; 44(6):1403-1413. PubMed ID: 27885039
[TBL] [Abstract][Full Text] [Related]
11. Elevated Levels of Cytokines Associated with Th2 and Th17 Cells in Vitreous Fluid of Proliferative Diabetic Retinopathy Patients.
Takeuchi M; Sato T; Tanaka A; Muraoka T; Taguchi M; Sakurai Y; Karasawa Y; Ito M
PLoS One; 2015; 10(9):e0137358. PubMed ID: 26352837
[TBL] [Abstract][Full Text] [Related]
12. SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels.
Suga T; Kikuchi O; Kobayashi M; Matsui S; Yokota-Hashimoto H; Wada E; Kohno D; Sasaki T; Takeuchi K; Kakizaki S; Yamada M; Kitamura T
Mol Metab; 2019 Jan; 19():1-12. PubMed ID: 30416006
[TBL] [Abstract][Full Text] [Related]
13. Dapagliflozin modulates glucagon secretion in an SGLT2-independent manner in murine alpha cells.
Solini A; Sebastiani G; Nigi L; Santini E; Rossi C; Dotta F
Diabetes Metab; 2017 Dec; 43(6):512-520. PubMed ID: 28499695
[TBL] [Abstract][Full Text] [Related]
14. Comparison of serum NO, TNF-alpha, IL-1beta, sIL-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus.
Doganay S; Evereklioglu C; Er H; Türköz Y; Sevinç A; Mehmet N; Savli H
Eye (Lond); 2002 Mar; 16(2):163-70. PubMed ID: 11988817
[TBL] [Abstract][Full Text] [Related]
15. Expression of glucose transporters in duodenal mucosa of patients with type 1 diabetes.
Bolla AM; Butera E; Pellegrini S; Caretto A; Bonfanti R; Zuppardo RA; Barera G; Cavestro GM; Sordi V; Bosi E
Acta Diabetol; 2020 Nov; 57(11):1367-1373. PubMed ID: 32617672
[TBL] [Abstract][Full Text] [Related]
16. A Systematic Investigation on Complement Pathway Activation in Diabetic Retinopathy.
Shahulhameed S; Vishwakarma S; Chhablani J; Tyagi M; Pappuru RR; Jakati S; Chakrabarti S; Kaur I
Front Immunol; 2020; 11():154. PubMed ID: 32117292
[TBL] [Abstract][Full Text] [Related]
17. Tumour necrosis factor α-308 G/a and -238 G/a polymorphisms as predicator of diabetic retinopathy in Egyptians.
Moemen LAAA; El Shahat Ebeid M; A Abdelazeem A; Kenawy M Kenawy M; M Osman Z
Arch Physiol Biochem; 2023 Oct; 129(5):1143-1151. PubMed ID: 33910435
[TBL] [Abstract][Full Text] [Related]
18. Cells of the immune system and their cytokines in epiretinal membranes and in the vitreous of patients with proliferative diabetic retinopathy.
Tang S; Scheiffarth OF; Thurau SR; Wildner G
Ophthalmic Res; 1993; 25(3):177-85. PubMed ID: 8336904
[TBL] [Abstract][Full Text] [Related]
19. LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose.
Powell DR; Smith M; Greer J; Harris A; Zhao S; DaCosta C; Mseeh F; Shadoan MK; Sands A; Zambrowicz B; Ding ZM
J Pharmacol Exp Ther; 2013 May; 345(2):250-9. PubMed ID: 23487174
[TBL] [Abstract][Full Text] [Related]
20. NLRP3 inflammasome activation is associated with proliferative diabetic retinopathy.
Loukovaara S; Piippo N; Kinnunen K; Hytti M; Kaarniranta K; Kauppinen A
Acta Ophthalmol; 2017 Dec; 95(8):803-808. PubMed ID: 28271611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
